Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocugen

1.00
-0.0400-3.85%
Post-market: 1.020.0198+1.98%17:03 EDT
Volume:4.30M
Turnover:4.35M
Market Cap:292.03M
PE:-4.86
High:1.06
Open:1.03
Low:0.9902
Close:1.04
Loading ...

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

GlobeNewswire
·
Yesterday

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Yesterday

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
15 Jul

Ocugen Inc. Stock Rises Thursday, Outperforms Market

Dow Jones
·
11 Jul

Ocugen Inc. Stock Advances 7.6%, Outperforms Market

Dow Jones
·
10 Jul

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
08 Jul

Ocugen Inc. Stock Advances 3.3%, Outperforms Market

Dow Jones
·
04 Jul

Ocugen Granted Extension to Meet Nasdaq Listing Requirements

TIPRANKS
·
02 Jul

Ocugen Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Reuters
·
02 Jul

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
01 Jul

Ocugen Inc. Stock Falls 4.5%, Underperforms Market

Dow Jones
·
28 Jun

Ocugen’s Strategic Spinout and NeoCart Platform Propel Buy Rating

TIPRANKS
·
26 Jun

Ocugen Inc. Stock Rallies 5.5%, Outperforms Market

Dow Jones
·
25 Jun

Ocugen (OCGN) Receives a Buy from Noble Financial

TIPRANKS
·
24 Jun

Ocugen Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Jun

Ocugen Inc. Stock Falls 7.4%, Underperforms Market

Dow Jones
·
24 Jun

BRIEF-Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement

Reuters
·
23 Jun

Ocugen Inc. and Carisma Therapeutics Finalize Merger to Advance NeoCart® Regenerative Therapy for Knee Cartilage Repair

Reuters
·
23 Jun

Carisma Therapeutics Inc - Orthocellix Stockholder to Own 90% of Combined Company Post-Merger

THOMSON REUTERS
·
23 Jun

Carisma Therapeutics Inc - Orthocellix to Merge Into Wholly-Owned Subsidiary of Carisma

THOMSON REUTERS
·
23 Jun